Fostering Open Collaboration for Paediatric Cancer Drug Development

Wong et al. describe in Biochemical Society Transactions how open collaboration and an open drug discovery model, like the one used by M4K Pharma, can help overcome the challenges faced while researching therapies for rare paediatric brain tumours such as DIPG.

Previous
Previous

Oxford Team Supports Brain Tumour Charity’s Twilight Walk

Next
Next

Oxford Team Shares First ALK2 Protein Structure Bound to M4K Compound